These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16391391)

  • 1. Intravenous immunoglobulin in immunodeficiency states: state of the art.
    Toubi E; Etzioni A
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):167-72. PubMed ID: 16391391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
    Pac M
    Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of intravenous immunoglobulins in the treatment of primary immunodeficiencies].
    Lewandowicz-Uszyńska A; Jankowski A
    Pol Merkur Lekarski; 2011 Jun; 30(180):409-12. PubMed ID: 21751549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
    Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
    Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin treatment in primary antibody deficiency.
    Maarschalk-Ellerbroek LJ; Hoepelman IM; Ellerbroek PM
    Int J Antimicrob Agents; 2011 May; 37(5):396-404. PubMed ID: 21276714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.
    Shapiro RS; Wasserman RL; Bonagura V; Gupta S
    J Clin Immunol; 2017 Feb; 37(2):190-196. PubMed ID: 24477950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New choices for treatment with subcutaneous immunoglobulins.
    Pleguezuelo DE; Sánchez-Ramón S
    Med Clin (Barc); 2017 Jan; 148(2):86-90. PubMed ID: 27919413
    [No Abstract]   [Full Text] [Related]  

  • 10. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
    Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
    J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders.
    Sanford M
    BioDrugs; 2014 Aug; 28(4):411-20. PubMed ID: 24925799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of patients with primary antibody deficiencies in Germany].
    Borte M; Oertelt C; Högy B
    Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.
    Landersdorfer CB; Bexon M; Edelman J; Rojavin M; Kirkpatrick CM; Lu J; Pfister M; Sidhu J
    Postgrad Med; 2013 Nov; 125(6):53-61. PubMed ID: 24200761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of intravenous immunoglobulin G (IVIG).
    Looney RJ; Huggins J
    Best Pract Res Clin Haematol; 2006; 19(1):3-25. PubMed ID: 16377538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.
    Wasserman RL
    Expert Rev Clin Immunol; 2014 Mar; 10(3):325-37. PubMed ID: 24527947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.
    Schroeder HW; Dougherty CJ
    Infection; 2012 Dec; 40(6):601-11. PubMed ID: 22968971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.